According to the latest news, the NDRC formulated and issued the “Three-year plan to enhance core competitiveness of manufacturing industries (2018-2020)." The plan states that by the end of the "13th Five-Year Plan", key areas of manufacturing industries will have broken through a number of key technologies for industrialization, formed a group of leading enterprises with international influence, built a batch of well-known Chinese-made brands and created a series of internationally recognized Chinese standards. And the innovation capability and the product quality of manufacturing industry will have obviously improved, as well as the overall quality. The Plan proposes a total of nine key manufacturing sectors that should focus on enhancing core competitiveness. The "industrialization of high-end medical devices and pharmaceutical key technologies" is listed.
In this area, the key tasks of industrialization are:
1. Speed up the industrialization and application of high-end medical devices.
Major support will be provided for the industrialization of innovative medical devices such as PET-MRI, ultrasound endoscopy, surgical robots, total laboratory automation (TLA) test and analysis pipeline. Support high-performance imaging devices such as PET-CT, CT and MRI, treatment devices such as high-energy linear accelerators and imaging-guided radiation therapy devices, in vitro diagnostic products such as high throughput gene sequencer, chemiluminescence immunity analyzer and new molecular diagnostic instruments, new implantable and interventional products such as full-degradable coronary stents, nerve stimulators, and materials inducing regeneration and repair of tissues organs, and the upgrading and quality performance improvement of high-end intelligent aids for rehabilitation and Point-of-care Testing (POCT) system.
2. Promote the industrialization and applications of high-end drugs.
It promotes the development and industrialization of innovative drugs with targeting ability, highly selectivity, new mechanism of action to treat cardiovascular diseases, diabetes, immune system disease, virus and drug-resistant infections and other major diseases. Support the development and industrialization of the off-patent first chemical generics and biosimilars with great market potential and high clinical value, and support the upgrading of the products and industries which pass the quality evaluation and efficacy evaluation of generic drugs. Support the industrialization of Class 1-2 new chemical drugs (new compounds and modified new drugs), new traditional Chinese medicines of 1-6 types (including national medicine) new classic and famous products, and the first domestic listed bio-pharmaceuticals that have obtained new drug certificates or have been declared as new drugs since 2015.
3. Strengthen the construction of specialized technical service platform.